# US 2025/0154241 A1 · Antigen binding proteins capable of binding thymic stromal lymphopoietin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154241 A1
- Document ID: US20250154241A1
- Status: Published application
- Kind: A1
- Application number: 19/022,014
- Filed: 2025-01-15
- Published: 2025-05-15
- Earliest claimed: 2007-09-10
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Michael R. Comeau; James F. Smothers; Bo-Rin P. Yoon; Christopher Mehlin
- Web page: https://patentgrep.com/patent/US20250154241A1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/244: {Interleukins [IL]}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.

## Claims

### Claim 1

An isolated antigen binding protein comprising an amino acid sequence selected from the group consisting of:
a. a light chain CDR3 sequence selected from the group consisting of:
i. a light chain CDR3 sequence that differs by no more than a total of two amino acid additions, substitutions, and/or deletions from a CDR3 sequence selected from the group consisting of the light chain CDR3 sequences of Al to All;
ii. QQAX8SFPLT (SEQ ID NO: 251);
and
b. a heavy chain CDR3 sequence selected from the group consisting of:
i. a heavy chain CDR3 sequence that differs by no more than a total of three amino acid additions, substitutions, and/or deletions from a CDR3 sequence selected from the group consisting of the heavy chain CDR3 sequences of Al to A27;
ii. GGGIX12VADYYX13YGMDV (SEQ ID NO: 255); and
iii. DX21GX22SGWPLFX23Y (SEQ ID NO: 259);
wherein
X8 is an N residue or a D residue;
Xi2 is a P residue or an A residue;
Xi3 is a Y residue or an F residue;
X21 is a G residue or an R residue;
X22 is an S residue or a T residue;
X23 is an A residue or a D residue,
and wherein said antigen binding protein specifically binds to TSLP.

### Claim 2 (depends on 1)

The isolated antigen binding protein of claim 1, further comprising an amino acid sequence selected from the group consisting of:
a. a light chain CDR1 sequence selected from the group consisting of:
i. a light chain CDR1 sequence that differs by no more than three amino acids additions, substitutions, and/or deletions from a light chain CDR1 sequence of A1-A27;
ii. RSSQSLX1YSDGX2TYLN (SEQ ID NO: 246);
iii. RASQX4X5SSWLA (SEQ ID NO: 249); and
b. a light chain CDR2 sequence selected from the group consisting of:
i. a light chain CDR2 sequence that differs by no more than two amino acid
additions, substitutions, and/or deletions from a CDR2 sequence of A1-A27;
ii. KVSX3WDS (SEQ ID NO: 247);
iii. X6X7SSLQS (SEQ ID NO: 250); and iv. QDX9KRPS (SEQ ID NO: 252);
c. a heavy chain CDR1 sequence selected from the group consisting of:
i. a heavy chain CDR1 sequence that differs by no more than two amino acid additions, substitutions, and/or deletions from a CDR1 sequence of A1-A27;
ii. X10YGMH (SEQ ID NO: 253); and
iii. X15Xi6YMX17 (SEQ ID NO: 257);
d. a heavy chain CDR2 sequence selected from the group consisting of:
i. a heavy chain CDR2 sequence that differs by no more than three amino acid additions, substitutions, and/or deletions from a CDR2 sequence of A1-A27;
ii. VIWX11DGSNKYYADSVKG (SEQ ID NO: 254);
iii. VISYDGSX14KYYADSVKG (SEQ ID NO: 256); and
iv. WrNPNSGGTNXi8X19X2OKFQG (SEQ ID NO: 258);
wherein
X1 is a V residue or an I residue;
X2 is an N residue or a D residue;
X3 is a Y residue or an N residue;
X4 is a G residue or a S residue;
X5 is a L residue or an I residue;
X6 is an N residue or a T residue;
X7 is a T residue or an A residue;
X9 is a K residue or an N residue;
X10 is an S residue or an N residue;
X11 is a Y residue or an F residue;
X14 is a Y residue or a N residue;
X15 is a D residue or G residue;
X16 is a Y residue or a D residue;
X17 is a Y residue or an H residue;
X18 is a Y residue or an H residue;
X19 is a V residue or an A residue;
X20 is a Q residue or an R residue,
and wherein said antigen binding protein specifically binds to TSLP.

### Claim 3 (depends on 1)

The isolated antigen binding protein of claim 1 comprising either:
a. a light chain variable domain comprising:
i. a light chain CDR1 sequence selected from A1-A27;
ii a light chain CDR2 sequence selected from A1-A27;
iii. a light chain CDR3 sequence selected from A1-A27, or b. a heavy chain variable domain comprising:
i. a heavy chain CDR1 sequence selected from A1-A27;
ii. a heavy chain CDR2 sequence selected from Al-All, and
iii. a heavy chain CDR3 sequence selected from A1-A27; or
c. the light chain variable domain of (a) and the heavy chain variable domain of (b).

### Claim 4 (depends on 1)

The isolated antigen binding protein of claim 1 comprising either:
a. a light chain variable domain sequence selected from the group consisting of;
i. amino acids having a sequence at least 80% identical to a light chain variable domain sequence selected from L1-L27;
ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding the light chain variable domain sequence of L1-L27;
iii. a sequence of amino acids encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of a light chain variable domain sequence of L1-L27;
b. a heavy chain variable domain sequence selected from the group consisting of:
i. a sequence of amino acids that is at least 80% identical to a heavy chain variable domain sequence of H1-H27;
ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding the heavy chain variable domain sequence of H 1-H27;
iii. a sequence of amino acids encoded by a polynucleotide sequence that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of a heavy chain variable domain sequence of H1-H27; or
c. the light chain variable domain of (a) and the heavy chain variable domain of (b), wherein said antigen binding protein specifically binds to TSLP.

### Claim 5

An isolated antigen binding protein, comprising either:
a. a light chain variable domain sequence selected from the group consisting of: L1-L27 b. a heavy chain variable domain sequence selected from the group consisting of: H1-H27; or,
c. the light chain variable domain of (a) and the heavy chain variable domain of (b), wherein the antigen binding protein specifically binds to TSLP.

### Claim 6 (depends on 5)

The isolated binding protein of claim 5, comprising a light chain variable domain sequence and a heavy chain variable domain sequence selected from the group consisting of: L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L1 OHl O, L1 I H1 1, L1 2H1 2,
L13.1H13, L13.2H13, L14.1H14, L14.2H14, L15.1H15, L15.2H15, L16.1H16, L16.2H16, L17H17, L18.1H18, L18.2H18, L19.1H19, L19.2H19, L20.1H20, L20.2H20, L21H21,
L22H22, L23H23, L24H24, L25H25, L26H26, and L27H27.

### Claim 7 (depends on 1, 5)

The isolated antigen binding protein of claim 1 or claim 5, wherein the binding protein binds to TSLP with substantially the same Kd as a reference antibody selected from the group of antibodies consisting of A2, A3, A4 and A5.

### Claim 8 (depends on 1, 5)

The isolated antigen binding protein of claim 1 or claim 5, wherein the binding protein inhibits TSLP activity according to the primary cell OPG assay with the same IC50 as a reference antibody selected from the group of antibodies consisting of A2, A3, A4, and A5.

### Claim 9 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is
selected from the group consisting of a human antibody, a humanized antibody, chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a monomeric antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an F(fa′)x fragment, a domain antibody, an IgD
antibody, an IgE antibody, and IgM antibody, and IgG1 antibody, and IgG2 antibody, and
IgG3 antibody, and IgG4 antibody, and IgG4 antibody having at least one mutation in the hinge region that alleviates a tendency to for intra H-chain disulfide bonds.

### Claim 10 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is a human antibody.

### Claim 11 (depends on 9, 10)

A pharmaceutical composition comprising the antibody of claim 9 or 10.

### Claim 12 (depends on 5)

An isolated nucleic acid comprising a polynucleotide sequence encoding the light chain variable domain, the heavy chain variable domain, or both, of the antigen binding agent of claim 5.

### Claim 13 (depends on 12)

The isolated nucleic acid of claim 12, wherein the sequence is selected from L1-L27; H1-H27, or both.

### Claim 14 (depends on 12)

A recombinant expression vector comprising the nucleic acid of claim 12.

### Claim 15 (depends on 14)

A host cell comprising the vector of claim 14.

### Claim 16 (depends on 10)

A hybridoma capable of producing the antibody of claim 10.

### Claim 17 (depends on 11, 15)

A method of producing the antibody of claim 11, comprising incubating the host cell of claim 15 under conditions that allow it to express the antibody.

### Claim 18 (depends on 11)

A method of treating a TSLP-related inflammatory condition in a subject in need of such treatment comprising administering a therapeutically effective amount of composition of claim 11 to the subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the inflammatory condition is selected from the group consisting of allergic asthma, allergic rhinosinusitis, allergic conjunctivitis, and atopic
dermatitis.

### Claim 20 (depends on 11)

A method of treating a TSLP-related fibrotic disorder in a subject in need of such treatment comprising administering a therapeutically effective amount of the composition of claim 11 to the subject.

### Claim 21 (depends on 20)

The method of claim 20, wherein the fibrotic disorder is selected from the group consisting of scleroderma, interstitial lung disease, idiopathic pulmonary fibrosis, fibrosis arising from chronic hepatitis B or C, radiation-induced fibrosis, and fibrosis arising from wound healing.

### Claim 22

An isolated antigen binding protein that cross-competes for binding TSLP with an antibody selected from the group consisting of A1-A27.

### Claim 23 (depends on 22)

The isolated antigen binding protein of claim 22, wherein the antigen binding protein
comprises an antibody heavy chain variable region and light chain variable region.

### Claim 24

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity higher than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K67E, K97E, K98E, R100E, K101 E, and K103E.

### Claim 25 (depends on 24)

The isolated antigen binding protein of claim 24, wherein antigen binding protein has a higher binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 26 (depends on 25)

The isolated antigen binding protein of claim 25, wherein antigen binding protein has a higher binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 27

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K21E, T25R, S28R, S64R, and
K73E.

### Claim 28 (depends on 27)

The isolated antigen binding protein of claim 27, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 29 (depends on 28)

The isolated antigen binding protein of claim 28, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 30 (depends on 27)

The isolated antigen binding protein of claim 27, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity higher than the wild-type affinity, wherein the second group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K67E, K97E, K98E, R100E, K101 E, and K103E.

### Claim 31

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity higher than the wild-type affinity, wherein the group of mutated TSLP includes mutated
TSLP comprising a mutation selected from the group consisting of K97E, K98E, R100E,
K101E, and K103E.

### Claim 32 (depends on 31)

The isolated antigen binding protein of claim 31, wherein antigen binding protein has a higher binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 33 (depends on 32)

The isolated antigen binding protein of claim 32, wherein antigen binding protein has a higher binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 34

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K10E, A14R, K.21 E, D22R, K73E, K75E, and A76R.

### Claim 35 (depends on 34)

The isolated antigen binding protein of claim 34, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 36 (depends on 35)

The isolated antigen binding protein of claim 35, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 37 (depends on 34)

The isolated antigen binding protein of claim 34, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity higher than the wild-type affinity, wherein the second group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K.97E, K98E, R100E, K101E, and K103E.

### Claim 38

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K12E, D22R, S40R, R122E, N124E, R125E, and K129E.

### Claim 39 (depends on 38)

The isolated antigen binding protein of claim 38, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 40 (depends on 39)

The isolated antigen binding protein of claim 39, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 41

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of S40R, S42R, H46R, R122E, and K129E.

### Claim 42 (depends on 41)

The isolated antigen binding protein of claim 41, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 43 (depends on 42)

The isolated antigen binding protein of claim 42, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 44

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of D2R, T4R, D7R, S42R, H46R, T49R, E50R, Q112R, R122E, R125E, and K129E.

### Claim 45 (depends on 44)

The isolated antigen binding protein of claim 44, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 46 (depends on 45)

The isolated antigen binding protein of claim 45, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 47 (depends on 44)

The isolated antigen binding protein of claim 44, wherein the antigen binding protein binds to a mutated TSLP comprising mutation K101 E with an affinity higher than the wild-type affinity.

### Claim 48

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of N5R, S17R, T18R, K21 E, D22R, T25R, T33R, H46R, A63R, S64R, A66R, E68R, K73E, K75E, A76R, A92R, T93R, Q94R, and A95R.

### Claim 49 (depends on 48)

The isolated antigen binding protein of claim 48, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 50 (depends on 49)

The isolated antigen binding protein of claim 49, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 51 (depends on 48)

The isolated antigen binding protein of claim 48, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity higher than the wild-type affinity, wherein the second group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K97E, K98E, R100E, K101E, and K103E.

### Claim 52

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K21E, K21R, D22R, T25R, T33R, S64R, K73E, K75E, E1 1 IR, and S114R.

### Claim 53 (depends on 52)

The isolated antigen binding protein of claim 52, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 54 (depends on 53)

The isolated antigen binding protein of claim 53, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 55 (depends on 52)

The isolated antigen binding protein of claim 52, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity higher than the wild-type affinity, wherein the second group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K97E, K98E, R100E, K101E, and K103E.

### Claim 56

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of E9R, K10E, K12E, A13R, S17R, S20R, K21E, K21 R, K73E, K75E, N124E, and R125E.

### Claim 57 (depends on 56)

The isolated antigen binding protein of claim 56, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 58 (depends on 57)

The isolated antigen binding protein of claim 57, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 59 (depends on 56)

The isolated antigen binding protein of claim 56, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity higher than the wild-type affinity, wherein the second group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K67E, K97E, K98E, R100E, K101E, and K103E.

### Claim 60

An isolated antigen binding protein that binds wild-type TSLP with a wild-type affinity, wherein the antigen binding protein binds to any of a group of mutated TSLP with an affinity lower than the wild-type affinity, wherein the group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of A14R, K21E, D22R, A63R, S64R, K67E, K73E, A76R, A92R, and A95R.

### Claim 61 (depends on 60)

The isolated antigen binding protein of claim 60, wherein antigen binding protein has a lower binding affinity for any two or more members of the group of mutated TSLP than the wild-type affinity.

### Claim 62 (depends on 61)

The isolated antigen binding protein of claim 61, wherein antigen binding protein has a lower binding affinity for all members of the group of mutated TSLP than the wild-type affinity.

### Claim 63 (depends on 60)

The isolated antigen binding protein of claim 60, wherein the antigen binding protein binds to any of a second group of mutated TSLP with an affinity higher than the wild-type affinity, wherein the second group of mutated TSLP includes mutated TSLP comprising a mutation selected from the group consisting of K97E, K98E, R100E, K101E, and K103E.
